2269 Stock Overview
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$12.90 |
52 Week High | HK$52.45 |
52 Week Low | HK$12.42 |
Beta | 0.62 |
1 Month Change | -7.99% |
3 Month Change | -57.00% |
1 Year Change | -72.44% |
3 Year Change | -88.29% |
5 Year Change | n/a |
Change since IPO | -83.23% |
Recent News & Updates
Recent updates
Shareholder Returns
2269 | HK Life Sciences | HK Market | |
---|---|---|---|
7D | -3.2% | 1.1% | 2.3% |
1Y | -72.4% | -66.6% | -10.9% |
Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -66.6% over the past year.
Return vs Market: 2269 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
2269 volatility | |
---|---|
2269 Average Weekly Movement | 14.8% |
Life Sciences Industry Average Movement | 10.7% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.5% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2269's share price has been volatile over the past 3 months.
Volatility Over Time: 2269's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 12,740 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
2269 fundamental statistics | |
---|---|
Market cap | HK$53.70b |
Earnings (TTM) | HK$3.67b |
Revenue (TTM) | HK$18.41b |
14.6x
P/E Ratio2.9x
P/S RatioIs 2269 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2269 income statement (TTM) | |
---|---|
Revenue | CN¥17.03b |
Cost of Revenue | CN¥10.21b |
Gross Profit | CN¥6.83b |
Other Expenses | CN¥3.43b |
Earnings | CN¥3.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.82 |
Gross Margin | 40.08% |
Net Profit Margin | 19.96% |
Debt/Equity Ratio | 4.9% |
How did 2269 perform over the long term?
See historical performance and comparison